Taro Pharmaceutical Industries (NYSE:TARO) announced its earnings results on Tuesday. The company reported $1.42 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.53 by ($0.11), MarketWatch Earnings reports. The business had revenue of $174.94 million for the quarter, compared to the consensus estimate of $168.25 million. Taro Pharmaceutical Industries had a net margin of 37.88% and a return on equity of 12.06%.
Shares of TARO opened at $70.05 on Friday. Taro Pharmaceutical Industries has a 52-week low of $56.07 and a 52-week high of $102.28. The stock has a 50 day moving average price of $66.60 and a 200 day moving average price of $77.13. The company has a market capitalization of $2.57 billion, a price-to-earnings ratio of 11.01 and a beta of 0.81.
Several brokerages recently issued reports on TARO. Zacks Investment Research lowered shares of Taro Pharmaceutical Industries from a “buy” rating to a “hold” rating in a research report on Thursday. HC Wainwright reiterated a “buy” rating and issued a $96.00 price target (up from $94.00) on shares of Taro Pharmaceutical Industries in a research report on Thursday.
Taro Pharmaceutical Industries Ltd., a science-based pharmaceutical company, engages in the development, manufacture, and marketing of pharmaceutical products in the United States, Canada, Israel, and internationally. It offers prescription and over-the-counter pharmaceutical products focusing on primary areas, including topical creams and ointments, liquids, capsules, and tablets in the dermatological and topical, cardiovascular, neuropsychiatric, and anti-inflammatory therapeutic categories.
Featured Article: 52 Week Highs
Receive News & Ratings for Taro Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Taro Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.